Pharmaceutical gelatin qualified for veterinary medicinal products is differentiated from food-grade material by compendial controls covering Bloom strength, viscosity, isoelectric point, peroxide value, elemental impurity screening, and endotoxin burden for parenteral applications. The downstream application profiles below address seven manufacturing routes: hard capsule shells, palatable soft chews, tablet granulation binding, injectable succinylated gelatin, lyophilized vaccine stabilization, oral solution suspension, and medicated premix carrier. Each profile specifies the applicable regulatory anchor, quantitative use range, production-equipment limitations observed on commercial lines, and terminal veterinary dosage form.

When Capsule Shell Gel Viscosity and Pin Withdrawal Speed Set Reject Rates on High-Speed Veterinary Capsule Lines

Manufacturing two-piece hard capsules for veterinary antibiotics and nutraceutical actives starts with a high-Bloom gelatin solution prepared at 28–35% w/w solids and held at 58–62 °C in a jacketed, stirred tank under vacuum. The gelatin used for the shell must satisfy the USP/NF Gelatin monograph, lot-to-lot Bloom strength within a negotiated range—commonly 180–250 g Bloom for veterinary capsule bodies—and residual moisture by USP <731> at 13.0–16.0% w/w on the finished shell. In capsule manufacturing, the addition ratio is not a blending calculation but a material-consumption parameter: the dry shell consists of essentially 100% w/w gelatin solids plus permitted plasticizer, opacifier, and water; if the same gelatin is used as a binder inside the encapsulated powder, the dry-granulation addition rate is 2–5% w/w of the fill mass. On the shell line, polished stainless steel pins are preheated to 60–70 °C and dipped into the gel mass with a withdrawal speed profile adjusted to the gel's apparent viscosity, typically 800–1,200 mPa·s at 60 °C measured by rotational viscometer with a small-sample adapter. The resulting shell wall is controlled to 0.09–0.13 mm. Drying tunnels run at 22–25 °C and 40–50% RH for 120–180 min; shells exiting above 16.0% w/w moisture show deformation and static adhesion on automatic capsule fillers, while shells below 13.0% w/w moisture exhibit cap cracking during high-speed joining. Finished empty shells are checked against USP <701> disintegration—complete shell rupture in water at 37±2 °C within 15 min—and USP <61>/<62> microbial limits before transfer to a filling line. Terminal dosage types include 25 mg, 50 mg, and 250 mg hard gelatin capsules for companion-animal antibiotic powders such as amoxicillin/clavulanate or doxycycline hyclate, as well as uncoated and enteric shells for specialist veterinary therapeutics.

What Addition Ratio Prevents Post-Extrusion Hardening in Palatable Soft Chews for Companion Animals?

Palatable soft chew formulations for dogs and cats place a specific tension on gelatin selection because the matrix must retain deformability after drying while preventing plasticizer migration to the surface. Veterinary-grade gelatin is dispersed with glycerol or sorbitol in a vacuum mixer; the dry solids ratio is maintained at 15–30% w/w gelatin in the final matrix, with humectant at 15–25% w/w and total water activity controlled to 0.60–0.70 using USP <1112>. Quantitative limits are process-critical rather than nominal: below 15% w/w gelatin the extrudate loses structural memory and collapses at the die face, while above 30% w/w gelatin the cooled chew hardens beyond acceptable palatability after 72 h at 25 °C/60% RH. The gelatin hydration step is performed at 60–70 °C under −0.7 to −0.9 bar vacuum to remove dissolved air; active pharmaceutical ingredients are added only after the mass cools to 40–45 °C, because thermolabile veterinary actives such as avermectins degrade under prolonged high-moisture heat. Compounding is followed by low-temperature twin-screw extrusion with an L/D ratio of 20:1–30:1, barrel zones set at 35 °C, 40 °C, and 42 °C, and a die pressure of 20–40 bar to avoid shear-induced gelatin chain scission. Cut pieces are dried in a dehumidified tunnel at 25 °C and 30% RH until water activity falls to 0.65. Release tests include USP <1217> breaking-force limits adapted for elastic bodies, with a target puncture force of 1.5–2.5 N and rebound compression returning at least 85% of original thickness within 30 s. Terminal dosage forms include beef- or chicken-flavored soft chews containing isoxazoline ectoparasiticides, milbemycin oxime/praziquantel combinations, and carprofen in 25 mg, 50 mg, and 100 mg veterinary presentations.

Sterile filtration pressure decay curves in veterinary parenteral gelatin manufacturing shift when the molecular mass distribution of the incoming gelatin broadens beyond the release range for succinylated gelatin, and this is detected on production lines as a differential-pressure increase across the 0.22 µm sterilizing-grade filter at constant peristaltic pump output. Injectable veterinary gelatin for plasma volume substitution is not a simple dissolution product; it is typically succinylated in aqueous phase to alter the isoelectric point and reduce antigenicity. The compliance anchor includes the USP/NF Gelatin monograph release, USP <71> sterility, USP <85> bacterial endotoxins—with product-specific limits commonly at 0.5 EU/mg or lower according to the parenteral monograph—USP <788> particulate matter in injections, USP <785> osmolality, and ICH Q3D elemental impurity screening using USP <232>/<233>. The final succinylated gelatin infusion is compounded at 4% w/v in 0.9% w/v sodium chloride injection, with average molecular weight controlled between 20,000 and 35,000 Da and pH adjusted to 7.1–7.7. In contrast, absorbable gelatin sponge manufacture uses a higher-solids gelatin foam, cast and lyophilized to a sponge density of 20–40 mg/cm³, then cut to surgical sizes. Upstream, gelatin is dissolved in water-for-injection at 40–50 °C, succinylated at pH 8.5–9.0, neutralized to 6.5–7.0, clarified through 0.45 µm followed by 0.22 µm membrane filtration, filled into flexible polyolefin bags, and terminally autoclaved at 121 °C for 15 min. Sponges are terminally sterilized by gamma irradiation or dry heat after residual ethylene oxide testing according to ISO 10993-7. Terminal dosage types include 500 mL intravenous infusion bags for equine and bovine hypovolemic support and sterile absorbable gelatin sponges used in abdominal or orthopedic veterinary surgery. Published data for specific veterinary batch failure rates in succinylated gelatin filtration are limited; manufacturer-specific filter capacity studies remain the practical release tool.

High-Shear Aqueous Granulation for Veterinary Tablet Compression: Binder Viscosity, Disintegration, and Hardness Trade-Offs

In veterinary tablet manufacture where moisture-sensitive beta-lactam actives such as clavulanate are blended with gelatin binder, the binder solution must be added at a rate that balances granule density against the disintegration window. Gelatin is dissolved at 5–10% w/w in deionized water at 50–60 °C, hydrated for 30–60 min, and then sprayed into a high-shear granulator at a dry-gelatin addition ratio of 2–4% w/w of the dry powder mass. Total granulation moisture at the end of wet massing is held at 8–12% w/w; water above 12% w/w causes balling on 6–8 mm screens and increases drying load beyond the fluid-bed unit's rated air volume. The high-shear mixer is operated at impeller 150–300 rpm and chopper 1,500–3,000 rpm, with binder spray at 0.8–1.5 kg/min per 100 kg batch and wet massing for 120–240 s. Granules are discharged through a 6–8 mm conical screen, dried in a fluid-bed dryer with inlet air 55–65 °C to a loss-on-drying of 1.5–2.5% w/w, and milled to a D50 of 150–250 µm. Compression is performed on a rotary tablet press with precompression 5–10 kN and main compression 8–12 kN, targeting 60–100 N tablet breaking force by USP <1217> and immediate-release disintegration by USP <701> within 15 min. Uniformity is confirmed by USP <905>; dissolution characterization uses USP <711> apparatus 2 at 50 rpm in 900 mL of buffered medium. Terminal dosage forms include 50 mg/12.5 mg amoxicillin/clavulanate tablets, 50 mg and 100 mg doxycycline hyclate tablets, and 23 mg carprofen tablets for companion animals. This segment yields a relatively narrow processing window: binder solution viscosity rises if the solution cools below 35 °C, causing uneven spray distribution and increased tablet friability.

In lyophilized live-attenuated veterinary vaccine matrices, gelatin functions as a volume-excluding stabilizer that reduces ice-crystal damage to viral antigen particles during shelf freezing and primary drying. The gelatin is dissolved in water-for-injection at 2–8 °C and incorporated into the final pre-lyo formulation at 1–3% w/v, commonly with a disaccharide such as sucrose or trehalose at 5–10% w/v to maintain a glassy state. Compliance for veterinary biologicals in the United States falls under 9 CFR Part 113 sterility and safety testing; EU and other global submissions rely on applicable European Pharmacopoeia sterility and mycoplasma general chapters, and gelatin intended for parenteral vaccines is expected to have a valid TSE/BSE certificate of suitability from the EDQM or equivalent. The formulation is mixed under low shear, sterilized through a 0.22 µm filter, and aseptically filled into Type I glass vials at 4 °C. The lyophilization cycle is designed around the collapse temperature of the gelatin-sucrose matrix: freezing to −45 °C at 0.8 °C/min, primary drying at shelf −25 °C and chamber pressure 0.1–0.2 mbar for 48–72 h, and secondary drying at 25 °C and 0.02 mbar for 12–24 h. Residual moisture by USP <921> is controlled to <3.0% w/w; vials exceeding this threshold show cake shrinkage and poor reconstitution time. Terminal dosage types include single-dose and ten-dose lyophilized vaccine vials reconstituted with 1 mL or 10 mL sterile diluent for subcutaneous injection in dogs, cats, poultry, or swine. No general published upper gelatin concentration for all vaccine antigens is available; antigen-specific stability studies must define the protective ratio.

Concentrate Viscosity Is Not a Dilution-Proof Suspension Property

Gelatin used as a suspending agent in veterinary oral solutions must maintain low-shear viscosity in the concentrated product because the final drinking-water dilution reduces polymer concentration below the structuring threshold. In a concentrate, gelatin is incorporated at 0.5–2.0% w/v to retard sedimentation of insoluble actives such as fenbendazole, sulfadiazine/trimethoprim, or toltrazuril. At 1:100 dilution into medicated drinking water, the gelatin concentration falls to 5–20 ppm and no longer provides rheological stabilization; the function is therefore confined to the packaged oral solution or the concentrated suspension before dosing. Compliance includes USP <911> viscosity, USP <791> pH, USP <61>/<62> microbial enumeration, USP <467> residual solvents, and finished-product container compatibility per USP <661.1>/<661.2> for plastic materials. The manufacturing process begins with cold hydration of gelatin in purified water at 20–25 °C for 30 min, followed by heating to 50 °C under low-shear stirring to avoid foam. After cooling to 30 °C, the API slurry is added and homogenized at 500–1,500 psi; pH is then adjusted to 5.0–6.0 with a citrate buffer to keep the gelatin below its isoelectric point and avoid charge-loss flocculation. The liquid is filled into amber HDPE or PET bottles with polypropylene induction-seal closures. Terminal dosage types include 100 mL, 250 mL, and 1 L oral suspensions for poultry, swine, and bovine administration, as well as concentrated oral syringes for equine anthelmintics. Viscosity outside 25–80 mPa·s at 25 °C in the finished concentrate is a common source of batch rejection because it alters draw-off volume in automatic dosing pumps.

Dry medicated premixes for swine and poultry require a binder that maintains granule particle-size distribution through pneumatic conveying and auger metering, and gelatin is applied as a low-level aqueous binder in 1–3% w/w on dry premix mass. For powdered concentrates, the gelatin binder is sprayed into a ribbon or paddle mixer as a 5–10% w/w solution at 50–60 °C, with the mixing shaft speed set to 30–80 rpm and spray bar pressure 0.2–0.4 MPa to avoid localized overwetting. The wet mass is passed through a basket extruder with 0.5–1.5 mm screen openings, spheronized at 300–800 rpm for 1–3 min, and dried in a fluid-bed unit with inlet air 45–55 °C to final moisture by USP <731> below 5.0% w/w. Gelatin at this addition level reduces segregation of low-dose actives and improves granule hardness during bulk bag discharge; above 3% w/w the dried granules become hygroscopic and can bridge in silo outlets at relative humidity above 60%. Compliance anchors include USP <616> bulk and tapped density, USP <1174> powder-flow characterisation via Hausner ratio and compressibility index, USP <61>/<62> microbial limits, and USP <467> residual solvents. Terminal dosage types include 1 kg, 5 kg, and 25 kg foil-lined premix bags containing coccidiostats, anthelmintics, or vitamin-mineral concentrates for feed-mill dilution. Premix granules containing gelatin should not be stored above 25 °C and 60% RH without a secondary moisture barrier, because the amorphous binder phase absorbs water and accelerates caking.